Iconovo AB is a Sweden-based company, which offers inhalation solutions for pharmaceutical companies. Solutions are based on the Companyâ€™s device platforms and include formulation, analytical testing and documentation. Iconovo Ab develops products, which are a part of device family and include: ICOres, reservoir devices, ICOone, disposable unit-dose devices, ICOcap, capsule-based devices and ICOpre, pre-metered devices. Moreover, the Company offers programs, which include development of generic inhalation products, where the products are registered based on therapeutic equivalence; development of inhalation products based on a generic application programming interface (API) and new chemical entity (NCE); as well as phase I-II clinical trials using ICOone.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-08	SEK 1.065	-1.84%	24,778
26-07-07	SEK 1.085	-1.81%	12,765
26-07-06	SEK 1.105	+2.79%	80,380
26-07-03	SEK 1.075	+7.50%	3,851
26-07-02	SEK 1.000	0.00%	117,586

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-07-08 EDT			5-day change	1st Jan Change
1.065 ^SEK	-1.84%		+6.50%	-6.58%

06-22	Iconovo AB (Publ.) and Lonza Group Ag Sign Strategic Collaboration Agreement	CI
06-22	Iconovo, Lonza Finalize Long-term Strategic Collaboration	MT

Market Cap	102M 10.52M 9.23M 8.52M 7.87M 14.92M 1.01B 15.22M 39.8M 493M 39.51M 38.65M 1.71B	P/E 2026 *	-26.6x	P/E 2027 *	-3.04x
Enterprise Value	63.42M 6.52M 5.71M 5.28M 4.88M 9.24M 624M 9.43M 24.64M 305M 24.47M 23.93M 1.06B	EV / Sales 2026 *	2.19x	EV / Sales 2027 *	-
Free-Float	39.74%	Yield 2026 *	-	Yield 2027 *	-

06-22	Iconovo AB (Publ.) and Lonza Group Ag Sign Strategic Collaboration Agreement	CI
06-22	Iconovo, Lonza Finalize Long-term Strategic Collaboration	MT
04-24	Iconovo AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-24	Iconovo Q1 net sales up at 0.7 mln SEK	RE
04-14	Iconovo appoints Anders Mañsson as CEO	RE
04-14	Iconovo AB Appoints Anders Månsson as Permanent CEO, Effective April 14, 2026	CI
03-17	Iconovo says no TO 1 was used for subscription	RE
03-02	Iconovo announces final outcome of rights issue	RE
02-25	Iconovo and Lonza sign LOI regarding strategic collaboration	RE
02-24	Iconovo AB (Publ.) and Lonza Signs LOI Regarding Strategic Collaboration	CI
02-12	Iconovo Q4 net sales SEK 504,000	RE
02-12	Iconovo AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-15	Iconovo Secures SEK1 Million Feasibility Study Contract for Nasal Delivery Platform	MT

07-03	Iconovo AB (publ) reintroduces liquidity provider agreement with Pareto Securities AB	AQ
06-29	Iconovo terminates liquidity provider agreement	AQ
06-22	Iconovo and Lonza sign Strategic Collaboration Agreement	AQ
04-24	Iconovo: Limited progress – Q1 review	AQ
04-14	Anders Månsson is appointed CEO	AQ

Iconovo AB Stock

Stocks

ICO

SE0010868943

Medical Equipment, Supplies & Distribution

Valuation: Iconovo AB

Chart: Iconovo AB

Latest news : Iconovo AB

Analysts' recommendations: Iconovo AB

Press Releases: Iconovo AB

Quotes and Performance

Course Extremes

Managers and Directors: Iconovo AB

Latest insider transactions

Medical Supplies

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

1 day	-1.84%
1 week	+6.50%
Current month	+1.43%
1 month	-13.77%
3 months	-10.50%
6 months	-5.75%
Current year	-6.58%

1 week	1	1.15
1 month	0.91	1.29
Current year	0.91	1.44
1 year	0.91	2.79
3 years	0.91	28.7
5 years	0.91	97.8
10 years	0.91	99.8

Manager	Title	Age	Since
Anders Månsson CEO	Chief Executive Officer	59	2025-10-30
Henrik Simonsen DFI	Director of Finance/CFO	63	2023-03-31
Mikael Arinder COO	Chief Operating Officer	62	2015-12-31

Director	Title	Age	Since
Mats Håkan Johansson CHM	Chairman	65	2012-12-31
Orest Lastow BRD	Director/Board Member	62	2012-12-31
Berndt David Lennart Axelsson BRD	Director/Board Member	67	2012-12-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
22-09-21	Mats Håkan Johansson	Buy	Founder	500	0.0057%
22-09-20	Johan Wäborg	Buy	Chief Executive Officer	1,000	0.0113%
22-09-15	Agneta Walhagen	Buy	Director	840	0.0095%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ICONOVO AB	-1.84%	+6.50%	-46.48%	-96.43%	10.52M
COLOPLAST A/S	-2.26%	+4.91%	-34.50%	-50.93%	13.64B
INTCO MEDICAL TECHNOLOGY CO., LTD.	-1.38%	+13.16%	+77.30%	+112.97%	4.28B
ZHENDE MEDICAL CO., LTD.	+0.08%	+2.21%	+328.80%	+219.42%	3.48B
WINNER MEDICAL CO., LTD.	+0.57%	-1.19%	-29.45%	-31.53%	2.41B
SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED	-2.73%	+0.31%	-46.05%	-69.37%	1.9B
JAFRON BIOMEDICAL CO.,LTD.	+0.56%	+1.62%	-28.51%	-26.74%	1.86B
TOP GLOVE CORPORATION BHD.	+0.75%	-0.74%	-2.90%	-21.18%	1.31B
RIVERSTONE HOLDINGS LIMITED	+3.66%	+0.59%	+26.87%	+33.86%	938M
GVS S.P.A.	0.00%	-0.23%	-23.70%	-21.59%	905M
Average	-0.26%	+2.46%	+22.14%	+4.85%	3.07B
Weighted average by Cap.	-1.13%	+4.18%	+25.79%	+9.07%

	2026 *	2027 *
Net sales	29M 2.98M 2.61M 2.41M 2.23M 4.23M 285M 4.31M 11.27M 140M 11.19M 10.94M 485M	-
Net income	-3M -308K -270K -250K -231K -437K -29.51M -446K -1.17M -14.44M -1.16M -1.13M -50.13M	-34M -3.49M -3.06M -2.83M -2.61M -4.95M -334M -5.05M -13.21M -164M -13.12M -12.83M -568M
Net Debt	-39M -4.01M -3.51M -3.24M -3M -5.68M -384M -5.8M -15.15M -188M -15.04M -14.72M -652M	1M 103K 90.1K 83.18K 76.87K 146K 9.84M 149K 389K 4.81M 386K 377K 16.71M